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Abstract
Introduction. Type 1 diabetes mellitus (T1DM) is associated with an autoimmune reaction to thyroid antigens including thyroid
peroxidase (anti-TPO) and thyroglobulin (anti-Tg).
Aims. We determined in children with T1DM the relationship of positive anti-thyroid antibodies to potential risk factors,
including, age, gender, duration of diabetes, and glutamic acid decarboxylase antibodies (anti-GAD).
Materials and methods. We studied 144 children and adolescents with T1DM. Their age was 12.3 ± 4.6 (mean ± SD) years, and
duration of diabetes was 4.6 ± 3.8 years. Anti-thyroid antibodies were determined using a luminescence method and anti-GAD
using an enzyme-linked immunosorbent assay.
Results. The prevalence rates of anti-thyroid antibodies among the children with T1DM in our study were: anti-TPO (17.4%),
anti-Tg (11.1%), and of both anti-thyroid antibodies (10.4%). The presence of serum anti-thyroid antibodies was positively
associated with age (16.6 years in those with positive tests versus 12.0 years in those with negative tests, P = 0.027), duration of
diabetes (7.4 versus 4.3 years, P = 0.031), and serum TSH (Thyroid-stimulating hormone) levels (4.8 versus 2.3 mIU/mL,
P = 0.002). The presence of both anti-thyroid antibodies was associated with female sex (boys: 4/75 (5.3%), girls: 11/69
(15.9%), chi-square = 6.44, P = 0.04). Subclinical autoimmune thyroiditis (SAIT) was present in 55.5% of the patients with
thyroid antibody-positivity and was positively associated with age (16.6 versus 12.0 years, P = 0.001) and diabetes duration (7.6
versus 4.2 years, P = 0.001). Multiple logistic regression analysis revealed that the development of anti-thyroid antibodies was
predicted by: 1) the presence of anti-GAD (odds ratio (OR) 1.45, 95% conﬁdence interval (CI) 1.09–1.92), 2) the presence of a
second anti-thyroid antibody (OR 134.4, 95% CI 7.7–2350.3), and 3) older age (OR 22.9, 95% CI 1.13–463.2).
Conclusions. Thyroid autoimmunity was associated with female gender, increasing age, long diabetes duration, the persistence
of anti-GAD, and with TSH elevation, indicating subclinical hypothyroidism.
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Introduction
Children with type 1 diabetes mellitus (T1DM) are
more prone to develop other organ-speciﬁc autoim-
mune diseases, among which autoimmune thyroiditis
(AIT) is more frequently encountered (1–4).
The prevalence of thyroid autoimmunity in patients
with T1DM has been reported to be two to four times
more frequent than in the general population. Thus in
adults the prevalence of positive anti-thyroid antibo-
dies in the general population has been reported to be
6.6%–10% (5,6) and in Greece 13.9% (7), while in
patients with T1DM it has been found to be higher,
ranging from 20% to 40% (8,9).
Concerning children and adolescents, the relative
prevalence in the general population was found to
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(12), while in children and adolescents with T1DM it
ranges from 19% to 23.4% (1–3). It is noteworthy that
there is no relative study from Greece.
Different factors have been associated with the
development of thyroid autoimmunity in the general
population, such as heredity, increasing age, female
gender, puberty, oestrogen use, pregnancy (12,13),
and an iodine-rich diet (14,15). In adults with
T1DM, female gender, increasing age, and the
presence of glutamic acid decarboxylase antibodies
(anti-GAD) have been associated with the develop-
ment of thyroid autoimmunity (4,16). Also in chil-
dren and adolescents with T1DM, previous studies
agree on the age and gender effect (1,3,4,17,18),
while there are very limited studies on the
signiﬁcance of the persistence of anti-GAD (4,16),
the age at diabetes diagnosis (1,4), and diabetes
duration (4,18,19) on the development of thyroid
antibody positivity.
The development of autoimmune thyroiditis in
children with T1DM has been associated with speciﬁc
genetic risk markers. Speciﬁcally, hyperthyroidism
has been related to the presence of HLA
DQA1*0301, DQB1*0301, DQB1*0201, and hypo-
thyroidism with HLA DQA1*0501 (18). The pres-
ence of DQB1*05 appears to be protective of the
development of AIT (20).
AIT is characterized by the production of auto-
antibodies against the thyroid gland, T-lymphocytic
inﬁltration of the gland, and subsequent development
of various degrees of thyroid dysfunction (21). These
autoantibodies are directed towards speciﬁc thyroid
gland proteins, which are thyroglobulin (Tg), a fun-
damental component of thyroid colloid, and thyroid
peroxidase (anti-TPO), an enzyme participating in
the production of thyroid hormones (22).
The prevalence of anti-TPO in children with
T1DM has been reported to be between 10% and
29.4% and that of anti-Tg between 8.7% and 14.4%
(8,23–25), while the coexistence of both anti-thyroid
antibodies has been reported in 5.9%–7% of the
patients (8,24,25). These antibodies are not usually
detected in the serum of T1DM children at diabetes
diagnosis, but they seem to appear later on in the
course of the diabetes in patients with the relative
genetic predisposition (1,19). In a recent study, the
presence of anti-thyroid antibodies at the onset of
T1DM was detected in only 16.7% of the patients
with thyroid autoimmunity (19).
Thus there are a limited number of studies thor-
oughly analysing the risk factors related to the
development of thyroid antibodies in children with
T1DM (4,19). It is noteworthy that there are also
very few studies on the effect of thyroid antibody
positivity on the growth and body mass index (BMI)
statusofchildren andadolescentswithT1DM(26,27).
Therefore the aims of the present study were to
identify, in Greek children and adolescents, the prev-
alence of thyroid antibody positivity and to determine
the effect of potential risk factors, such as current age,
age at onset of diabetes, duration of diabetes, and
persistence of pancreatic autoimmunity (anti-GAD),
on its development. Moreover we studied the possible
effect of subclinical autoimmune thyroiditis on the
growth and BMI status of children with T1DM.
Patients and methods
The study population included 144 children and ado-
lescents (male/female: 77/67) with T1DM, followed
up in our out-patients’ diabetic clinic. The mean age
(± SD) of the patients was 12.3 ± 4.6 years, with a
mean age at T1DM diagnosis of 7.7 ± 3.6 years and a
mean diabetes duration of 4.6 ± 3.9 years. The study
was approved by the local Ethical Committee.
Informed consent was obtained from each parent
and/or patient before blood sampling.
The criteria for the diagnosis of T1DM diagnosis
were: fasting plasma glucose levels of 126 mg/dL (7.0
mmol/L), or symptoms of hyperglycaemia (polyuria,
polydipsia, and unexplained weight loss with a ran-
dom plasma glucose ‡200 mg/dL (11.1 mmol/L), or
2-hour plasma glucose ‡200 mg/dL (11.1 mmol/L)
during an oral glucose tolerance test (28). Apart from
marked hyperglycaemia, the diagnosis of T1DM is
usually associated with the presence of diabetic ketoa-
cidocis (DKA) (29). Among our patients, 70.6%
presented with DKA (pH < 7.30) and 29.4% without
(pH ‡ 7.30). Thus 32.4% had severe DKA
(pH < 7.10), 20.5% moderate (pH 7.10–7.19), and
17.7% mild DKA (pH 7.20–7.29). In the group
without DKA (29.4%), ketones were present in the
urine in 14% of the patients.
However there are additional serological markers of
the autoimmune process that indicate and can predict
T1DM,suchasglutamicaciddecarboxylaseantibodies
(anti-GAD) and islet antigen (IA-2) (30). Moreover
c-peptide, an indicator of residual insulin production,
is used for the differentiation between T1DM and
T2DM (31). Among our patients, 66 (53.2%) were
anti-GAD positive, while IA-2 and c-peptide levels
were not routinely measured.
During each hospital visit, the patients were clini-
cally examined, including thyroid gland palpitation,
blood pressure measurement, and assessment of their
pubertal statusandgrowth.Thusheight was expressed
as height standard deviation scores (Ht-SDS) and
body-weight as body mass index (BMI).
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was drawn cross-sectionally from each patient for auto-
antibody estimation, and sera were immediately stored
at -20C. Data on growth status and glycaemic control,
as well as on previous autoantibody estimations, were
recorded from the patients’ medical histories.
Enzyme-linked immunosorbent assay was used to
detect anti-GAD antibodies (Euroimmun AG, Ger-
many), performed with DYNEX DSX ELISA analy-
ser. Isoform GAD65 from human recombinant
glutamic acid decarboxylase was used. For the anti-
GAD antibodies, the upper limit of the normal range
was set at 10 IU/mL, and any greater value was
considered as positive.
Anti-Tg and anti-TPO antibodies were detected
using the luminescence method (ILMA, Nichols,
Germany), performed with the Advantage analyser.
The upper normal limit for anti-Tg antibodies was set
at 100 IU/mL, while that for the anti-TPO antibodies
was set at 16 IU/mL. Values greater than these cut-off
values were considered as positive. For the evaluation
of thyroid function, T4 (thyroxine), T3 (triiodothy-
ronine), FT4 (Free-thyroxine), and FT3 (Free-
triiodothyronine) levels were measured using the elec-
trochemiluminescence method (CLIA) (Roche Diag-
nostics, France) on an ELECSUS 2010 analyser.
Thyroid ultrasonography was performed in all
patients with elevated titres of anti-thyroid antibodies,
combined with thyroid enlargement and/or elevated
TSH levels. The presence of thyroid enlargement
(thyroid gland volume >97th age-related percentile)
(32) with diffuse hypoechogenicity and/or diffuse
micronodules conﬁrmed the diagnosis of autoim-
mune thyroiditis (33). The diagnosis of subclinical
autoimmune thyroiditis (SAIT) (Hashimoto’s) was
based on high levels of TSH (>5 mIU/mL), associated
with the presence of at least one thyroid autoantibody
on two or more consecutive occasions, and/or with
ultrasonographic ﬁndings of thyroiditis (33). Clinical
hypothyroidism was associated, in addition to the
above, with low FT4 levels and/or the presence of
goitre. In all cases of hypothyroidism (subclinical or
clinical) with positive anti-thyroid antibodies, with/
without goitre, L-thyroxine administration was started.
Glycosylated haemoglobin A1c (HbA1c) was mea-
sured as an index of metabolic control on a DCA 2000
analyser. The normal range was 4.4%–6.4%.
Statistical analysis
Data were analysed using SPSS version 13.0 (SPSS,
Chicago, IL). The unpaired Student’s t test was
performed for the comparison of means, and the
chi-square test was used to compare percentages
among different subgroups of patients. Multiple
logistic regression analysis was used to assess the
independency and strength of associations and to
describe a predictive model.
Results
Altogether 144 children and adolescents with T1DM
(males/females: 75/69) were included in the present
study, with a mean ± SD age of 12.35 ± 4.64 years
(range 2.00–20.4), a mean ± SD age at diagnosis of
diabetes of 7.74 ± 3.6 years (range 0.20–13.4), and a
mean ± SD duration of diabetes of 4.66 ± 3.99 years
(range 0.60–16.00). The mean ± SD HbA1c levels
during the study period were 8.18% ± 1.68% (range
5.6%–14.4%), and the mean BMI of the patients was
20.60 ± 3.75 kg/m
2 (range 13.6–35.09).
Among our patients, 66 (53.2%) were positive for
anti-GAD antibodies and 26/144 (18.0%) for anti-
thyroid antibodies; 25 of the 144 patients (17.4%)
were positive for anti-TPO and 16/144 (11.1%) for
anti-Tg; 10 of the patients (6.9%) were positive only
for anti-TPO, and 2 of 144 (1.3%) were positive only
for anti-Tg. A total of 15 (10.4%) patients were
positive for both anti-TPO and anti-Tg.
In 4 of 27 patients (14.8%) tests for anti-thyroid
antibodies were positive at the time of diagnosis of
T1DM. Tests for anti-TPO antibodies became pos-
itive an average of 3.4 ± 3.5 (range 0–11) years after
the diagnosis of T1DM. Tests for anti-Tg antibodies
became positive 6.6 ± 3.5 years (range 1–13.0) after
the diagnosis of T1DM. Tests for both anti-TPO and
anti-Tg antibodies became positive 5.2 ± 2.9 years
(range 0.4–10.0) after the diagnosis of T1DM.
Factors contributing to the manifestation of
thyroid autoimmunity
The prevalence of anti-thyroid antibodies was posi-
tively associated with diabetes duration (Table I) and
age (Table II), with the highest prevalence rates
observed in patients with a diabetes duration of
‡6 years (P = 0.014) or an age of ‡15 years.
A multiple logistic regression model was developed
to analyse the effect of various factors, such as age,
gender, age at T1DM diagnosis, diabetes duration,
and the presence of pancreatic autoimmunity (anti-
GAD) on the development of each thyroid antibody
(Table III). Logistic regression analysis showed that
the appearance of anti-Tg and anti-TPO antibodies
was determined by age. Thus an increase of the age at
diabetes diagnosis by 1 year increased the probability
of thyroid antibody positivity by 15%. Moreover, a
signiﬁcant positive association between the prevalence
of anti-Tg antibodies and current age was observed
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one type of anti-thyroid antibody increased the prob-
ability for the development of the other type of anti-
thyroid antibody (OR 134.4). Finally the presence of
anti-GAD was associated with a 2-fold greater risk for
the development of anti-Tg (OR 1.45). However,
given the effect of current age, age at diagnosis, and
pancreatic autoimmunity, which were included in the
logistic regression model, diabetes duration did not
increase the probability of thyroid antibody positivity.
Characteristics of patients with different types of anti-
thyroid antibodies
We divided our study population into three groups
according to the number of detected anti-thyroid anti-
bodies. One group had negative tests for anti-thyroid
antibodies,onegrouphadoneoftwotestspositive,and
the third group had both tests positive for anti-thyroid
antibodies (Table IV). The group of children with
double thyroid antibody positivity were older and
had a longer duration of diabetes than the other groups
(P = 0.027 and P = 0.031 respectively). They also had
elevated serum TSH concentrations (4.8 ± 1.6 mIU/L)
but normal serum T4 levels (8.8 ± 1.1 mcg/dl), consis-
tent with subclinical hypothyroidism. In contrast, serum
TSH concentrations were lower (3.8 ± 1.9 mIU/L) in
the group with only one of two positive tests. Females
predominated in the group with double thyroid anti-
body positivity (boys 4/75 (5.3%), girls 11/69 (15.9%),
chi-square = 6.44, P = 0.04).
Thyroid status of children with anti-thyroid antibodies
At the time that anti-thyroid antibodies were ﬁrst
noted to be positive all patients were euthyroid with
a mean age of 10.7 ± 4.24 years (range 3.2–19.0) and a
mean diabetes duration of 3.5 ± 3.5 (range 0–11.0)
years. After 3.1 ± 2.8 years (range 0–7 years), a
progression towards subclinical hypothyroidism due
to Hashimoto’s thyroiditis was observed in 15 of 27
(55.5%) patients. This diagnosis was based on the
presence of elevated serum TSH concentrations (>5
mIU/mL) and normal T4 values, associated with a
positive test for at least one anti-thyroid antibody,
and/or with ultrasonographic ﬁndings of thyroiditis.
Serum TSH levels in patients with subclinical hypo-
thyroidism due to Hashimoto’s thyroiditis were
5.16 ± 2.6 mIU/L, and serum T4 levels were normal
(8.8 ± 1.1 mg/dL), while no patient developed clinical
hypothyroidism. Out of 27 patients 7 (25.9%) devel-
oped thyroid enlargement (goitre) together with anti-
thyroid antibody positivity, and another 8 patients
developed diffuse hypoechogenicity without thyroid
Table I. Prevalence of positive autoantibodies in children with
T1DM according to diabetes duration.
Diabetes
duration
0–2.9 years
Diabetes
duration
3.0–5.9 years
Diabetes
duration
‡6 years
P
n = 65 n = 32 n = 46
Anti-GAD
antibodies:
Anti-GAD(+) 61.5% 45.8% 47.5% NS
Anti-thyroid
antibodies:
Anti-TPO(+) 9.2% 15.6% 30.4% 0.014
Anti-Tg(+) 3.1% 3.1% 28.3% 0.001
Anti-TPO(+)
and anti-Tg(+)
3.0% 3.1% 26.0% 0.001
Table II. Prevalence of positive autoantibodies in children with
T1DM according to current age.
Current age
5–9.9 years
Current age
10–14.9 years
Current age
‡15 years
P
n = 34 n = 62 n = 39
Anti-GAD
antibodies:
Anti-GAD(+) 40.7% 62.3% 47.1% NS
Anti-thyroid
antibodies:
Anti-TPO(+) 8.8% 11.3% 25.0% 0.033
Anti-Tg(+) 2.9% 6.5% 22.2% 0.001
Anti-TPO(+)
and anti-Tg(+)
2.9% 6.4% 25.6% 0.002
Table III. Logistic regression analysis for the estimation of the
factors associated with autoantibody positivity in children with
T1DM.
BP -value OR 95% CI
Anti-Tg(+) versus
Anti-Tg(-):
Anti-TPO 4.90 0.001 134.4 (7.7–2350.3)
Current age
(years)
0.37 0.041 22.9 (1.13–463.2)
Anti-GAD 3.13 0.01 1.45 (1.09–1.92)
Anti-TPO(+) or/and
anti-Tg(+) versus
anti-TPO(-) and
anti-Tg(-):
Age at diabetes
diagnosis (years)
0.15 0.044 1.16 (1.00–1.35)
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thyroiditis (n = 15) were older (16.6 versus 12.0 years,
P = 0.001) and had a longer diabetes duration (7.6
versus 4.2 years, P = 0.001) than the rest of the study
population.
After the diagnosis of subclinical hypothyroidism,
they received treatment with L-thyroxine at a dose of
100 mg/m
2 of body surface area.
Effect of subclinical autoimmune thyroiditis on the
growth and BMI status of children with T1DM
No signiﬁcant effect of anti-thyroid antibody positiv-
ity on the growth and BMI status of the children with
diabetes was observed (Ht-SDS 0.062 versus 0.18,
P = NS, BMI 21.7 versus 20.5 kg/m
2, P = NS).
Discussion
The present study reports on the prevalence of thyroid
antibody positivity and of subclinical autoimmune
thyroiditis in children and adolescents with T1DM
in Greece and on the risk factors for its development.
It is noteworthy that there is no relative previous
study, to our knowledge, in Greece. Among the
novelties of our study are the association of thyroid
autoimmunity with the presence of anti-GAD, the
effect of age at diabetes diagnosis and diabetes dura-
tion on the development of thyroid autoimmunity, the
long-term follow-up of the patients and the progress
from thyroid antibody positivity to subclinical and
clinical hypothyroidism, and also the effect of sub-
clinical hypothyroidism on the children’s growth. To
our knowledge there are very limited studies in the
literature on the above topics.
The prevalence rate of anti-thyroid antibodies in
the T1DM patients of our study was 18.75%, while a
signiﬁcant percentage (55.5%) of them presented
subclinical autoimmune thyroiditis relatively early
in the course of the disease. Our ﬁndings are in
agreement with previous studies in this age-group,
reporting a prevalence of thyroid antibody positivity of
10%–23.4% (1,19,34), and of SAIT of 45% (1). It is
worth mentioning that the prevalence rates of thyroid
antibody positivity in adult T1DM patients are higher
than the ones in children and adolescents and range
from 20% to 40% (with the highest rates observed in
middle-aged women) (35), while the prevalence of
autoimmune thyroiditis in the general population
ﬂuctuates from 6.6% to 13.9% (5–7).
In our patients’ group we have noticed a signiﬁcant
association between the double thyroid antibody pos-
itivity and/or SAIT with female sex. Similar ﬁndings
have been previously observed (25,36). Speciﬁcally,
De Block et al. (36) reported a 3-fold risk of anti-TPO
antibody positivity in female adolescents and young
adults with diabetes in comparison with males. Also in
the general population, girls are more prone to
develop thyroid disease than boys (12). Actually,
sex hormones have been reported to affect the devel-
opment of antibodies (36). In patients with T1DM
(37) and also in an animal model of autoimmune
thyroiditis (38), oestradiol seemed to accelerate the
progression of autoimmune diseases via enhancing
the pathway of T helper type 2 (Th2) cells, while
androgens had a protective effect (39).
In this study, the prevalence of thyroid antibodies
increased with increasing age and diabetes duration.
Our ﬁndings are in agreement with previous studies
(1,36), reporting that the highest prevalence of thy-
roid antibodies was observed after the age of 15 years,
or after a diabetes duration of 3.5 years. This
Table IV. Characteristics of children with T1DM according to the presence or the absence of anti-thyroid antibodies.
Absence of thyroid
antibodies
One thyroid antibody
positive (+)
Both thyroid antibodies
positive (+)
P
n = 117 n = 12 n = 15
Current age (years) 12.0 ± 4.8 11.9 ± 5.6 16.6 ± 4.7 0.027
Age at diabetes diagnosis (years) 7.8 ± 3.8 8.2 ± 3.9 8.9 ± 4.7 NS
Males (n = 75) 62 (82.6%) 9 (12%) 4 (5.3%) chi-square = 6.44
Females (n = 69) 55 (79.7%) 3 (4.3%) 11 (15.9%) P = 0.04
Diabetes duration (years) 4.3 ± 3.7 3.8 ± 2.7 7.4 ± 4.5 0.031
BMI (kg/m
2) 20.5 ± 3.5 20.9 ± 4.6 21.4 ± 4.9 NS
HtSDS 0.20 ± 1.21 0.22 ± 0.72 0.16 ± 1.0 NS
T4 (mg/dL) 9.2 ± 2.5 9.2 ± 1.1 8.8 ± 1.1 NS
TSH (mIU/L) 2.3 ± 0.8
a 3.8 ± 1.9 4.8 ± 1.6
b NS
a versus
b: P = 0.002.
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ﬁnal phase of a process starting with autorecognition,
passing through immunity with the appearance of
autoantibodies, and ﬁnally leading to cell destruction
and autoimmune disease (39). Moreover it is known
that the maximum autoimmune activity is observed
during puberty (39). Actually in our study, although
the role of diabetes duration in the development of
thyroid antibody positivity was found to be signiﬁcant
in the univariate analysis, in the multivariate analysis it
was eliminated, given the effect of age. This could be
explainedbythefactthatinadolescentgirls,apartfrom
diabetes duration, the presence of female hormones
may signiﬁcantly contribute to the development of
thyroid autoimmunity.
Another interesting ﬁnding of the present study was
that there was no signiﬁcant effect of subclinical auto-
immune hypothyroiditis on growth and BMI status in
T1DM patients, which is in agreement with certain
studies (1,27). However, Chase et al. (26) reported
reduced growth rates in children with T1DM and
subclinical hypothyroidism, particularly in those
with TSH levels ‡10 mIU/L, while thyroid hormone
replacement therapy led to improved growth only in
prepubertal patients. Thus the clinical importance of
the early detection and treatment of SAIT in children
and adolescents with T1DM could be the prevention
of growth impairment. In terms of the BMI status of
children with diabetes and thyroid autoimmunity, no
signiﬁcant effect was observed in our study, which is in
agreement with previous studies (22,24).
We also observed an increase of TSH levels,
directly proportional to the degree of anti-thyroid
antibody positivity, with the lowest values occurring
in the group without thyroid autoimmunity and the
highest ones in the group with double thyroid anti-
body positivity. A possible explanation for this obser-
vation could be that in the presence of both thyroid
antibodies, the immune stimulation is probably more
intense, resulting in thyroid dysfunction. However, it
is not known whether these organ-speciﬁc autoanti-
bodies are directly involved in the pathophysiologic
mechanism of thyroid gland destruction or whether
they are associated with tissue destruction by thyroid-
inﬁltrating T cells (40). In previous studies, anti-TPO
antibodies seemed to be more speciﬁc markers of
thyroid gland function, as patients with positive
anti-TPO antibodies had higher TSH levels than
those with positive anti-Tg antibodies (1,41). In the
present study, TSH levels did not signiﬁcantly differ
between the above two groups of patients.
An important observation of our study was the
association of thyroid autoimmunity with the persis-
tence of pancreatic autoimmunity. This ﬁnding is in
agreement with another study (4), reporting that
T1DM patients with anti-GAD positivity had a
2-fold greater risk for the development of thyroid
autoimmunity than those without anti-GAD.
A possible explanation for this association could be
thatanti-GADantibodiesarenotexclusivelypresentin
the brain and pancreas but can also be found in other
tissues, such as the follicle cells of the thyroid gland
and also the parietal cells of the stomach (42,43). Thus
the persistence of anti-GAD antibodies could be a
marker for the future development of autoimmunity
against the thyroid gland and other organs.
In conclusion, the presence of thyroid antibody
positivity and the subsequent development of subclin-
ical autoimmune thyroiditis were quite prevalent
among the children and adolescents with T1DM of
our study, while the possible risk factors for its devel-
opment were older age ‡15 years, female gender, long
diabetes duration, and the persistence of anti-GAD.
Subclinical hypothyroidism was not found to affect
the children’s growth and BMI status. Thus, it is
suggested that all patients with T1DM should be
screened for autoimmune thyroiditis upon diagnosis
and then yearly, and in case of thyroid antibody
positivity they should be regularly followed up in
terms of their thyroid function and growth status.
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